Thus, combining NfL with advanced neuroimaging measures may enable increased understanding of MS pathophysiology and improved prognosis prediction as well as treatment responses monitoring (Bridel et al., 2021, Ineichen et al., 2021, Joisten et al., 2021, Preziosa et al., 2020, Saraste et al., 2021). The gene discussed is NEFL; the disease is myeloid sarcoma.